Stay updated on Switch to Dolutegravir + Rilpivirine Clinical Trial

Sign up to get notified when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Switch to Dolutegravir + Rilpivirine Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to switching to Dolutegravir + Rilpivirine from the current antiretroviral regimen in HIV-1 infected adults.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:28.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as general health condition and prior treatments. Additionally, the 'Eligibility Criteria Description' now includes specific inclusion criteria for participants, emphasizing their ability to comply with protocol requirements and complete the study as planned.
    Difference
    50%
    Check dated 2024-05-22T21:33:31.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T23:17:24.000Z thumbnail image

Stay in the know with updates to Switch to Dolutegravir + Rilpivirine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.